Atea Pharmaceuticals(AVIR)
Search documents
Atea Pharmaceuticals(AVIR) - 2021 Q3 - Earnings Call Transcript
2021-11-12 04:18
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2021 Earnings Conference Call November 11, 2021 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman & Chief Executive Officer Janet Hammond - Chief Development Officer Andrea Corcoran - Chief Financial Officer & Executive Vice President of Legal Conference Call Participants Jonathan Miller - Evercore ISI Tim Lugo - William Blair Roanna Ruiz - SVB Leerink Op ...
Atea Pharmaceuticals(AVIR) - 2021 Q2 - Earnings Call Transcript
2021-08-13 02:58
Call Start: 16:30 January 1, 0000 5:08 PM ET Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2021 Earnings Conference Call August 12, 2021 04:30 PM ET Company Participants Jonae Barnes - SVP, Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman and CEO Janet Hammond - Chief Development Officer Andrea Corcoran - CFO and EVP, Legal John Vavricka - Chief Commercial Officer Conference Call Participants Eric Joseph - J.P. Morgan Jonathan Miller - Evercore Lachlan Hanbury-Brown - ...
Atea Pharmaceuticals(AVIR) - 2021 Q1 - Earnings Call Transcript
2021-05-14 21:03
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President, Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman and CEO Janet Hammond - Chief Development Officer Andrea Corcoran - Chief Financial Officer and Executive President, Legal John Vavricka - Chief Commercial Officer Conference Call Participants Eric Joseph - J.P. Morgan Matthew Harrison - Morgan Stanley Jonathan Mi ...
Atea Pharmaceuticals(AVIR) - 2020 Q3 - Quarterly Report
2020-12-10 21:13
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaw ...